The cholesterol nobody treats
An inherited cholesterol-like particle raises heart-attack risk and has no treatment. Several drugs now lower it; the question is whether that prevents heart attacks.
40%likely
Well sourced
Next check
Digging in
Why it is different
The edge is not whether it works. It is that the market will read the coming trial result as a final verdict when it is only a halfway look.
Why it matters
It affects roughly one person in five and there is nothing to offer them today.
Next check · 9 Nov 2026
Is the Lp(a)HORIZON trial presented in a headline session at the American Heart Association meeting in November 2026?
How we scored it ·
from how often this kind of thing happens
If right, how big5/5How overlooked3/5Upside vs downside3/5Source trust5/5Independent sources3/5
The exact wording we score
At least one Lp(a)-lowering therapy reports a statistically significant MACE reduction in Phase 3 and gains approval for CV risk reduction by end-2030.